The sales of tibial neuromodulation devices are projected to rise at a CAGR of 8.1% during the forecast period 2022 to 2032. The global tibial neuromodulation devices market size is anticipated to be valued at US$ 97.7 Million in 2022 and is projected to surpass US$ 230.7 Million by 2032.
Rising urological illness incidence, increased demand for minimally invasive procedures, and outpatient usage are the factors driving tibial neuromodulation devices' market expansion over the projection period. The use of tibial neuromodulator devices is becoming more widespread, providing surgeons with the power, precision, and control required for soft or hard tissue, bone modulation.
High treatment costs and a lack of understanding about the devices and other treatment options available in the market are some of the factors affecting the demand for tibial neuromodulation devices.
| Attribute | Details |
|---|---|
| Tibial Neuromodulation Devices Market Value (2022) | US$ 97.7 Million |
| Tibial Neuromodulation Devices Market Anticipated Value (2032) | US$ 230.7 Million |
| Tibial Neuromodulation Devices Projected Growth Rate (2022 to 2032) | 8.1% |
Tibial neuromodulation devices work either by actively stimulating the neurons to cause a biological reaction or by directly applying for targeted pharmacological medicines in modest dosages to the area of action. Electrodes are applied to the spinal cord, brain, or peripheral nerves by neurostimulation devices.
The growing number of people suffering from ailments such as urine incontinence, Parkinson's disease, spinal cord damage, migraine, and epilepsy is driving the sales of tibial neuromodulation devices. The tibial neuromodulation devices market is also projected to benefit from increased awareness of neurodegenerative and neurological illnesses, as well as expanded application areas.
Growth opportunities in the tibial neuromodulation devices market include expanding market share through mergers and acquisitions and investing in new economies, as well as technological advancements in percutaneous tibial neuromodulation devices, which are driving the tibial neuromodulation devices market growth.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The rising frequency of chronic conditions, combined with the limits of pharmaceutical medications in effectively treating these diseases, has propelled the demand for tibial neuromodulation devices. The functional capabilities of various nerves in the human body, as well as the consequences of electrical stimulation of these nerves for the therapy of various illnesses, have been continuously explored. As a result, new strategies and gadgets for addressing and treating chronic illnesses have emerged, boosting the tibial neuromodulation devices market growth.
These treatments range from spinal cord stimulation for pain relief to vagus nerve stimulation for epilepsy and other diseases. The tibial neuromodulation devices market is characterized by the introduction of specialized devices and methodologies to treat specific illnesses, as well as ongoing improvements in neurostimulation techniques.
A considerable proportion of patients suffering from chronic diseases such as chronic back pain, depression, epilepsy, and sleep apnea, among others, are resistant to treatment and drugs. Resistance is seen in the treatment's slow progression and delayed or limited consequences. As a result, healthcare professionals are moving their focus to neurostimulation approaches for chronic disease treatment, which is driving the sales of neuromodulation devices during the forecast period.
According to the Centers for Disease Control and Prevention (CDC), an estimated 50 million people in the United States suffer from chronic pain each year, with an additional 19 million suffering from severe chronic pain. Epilepsy, treatment-resistant depression, and other chronic illnesses impose a significant financial burden on countries. As a result, the tibial neuromodulation devices market share is anticipated to rise significantly during the forecast period.
In growing countries such as China, Brazil, and India, the prevalence of neurological diseases such as epilepsy, depression, and others is increasing at a rapid pace. Despite a higher frequency, lower diagnostic rates in developing nations limit the number of individuals who require treatment. As a result of this, the sales of tibial neuromodulation devices are anticipated to decline over the forecast period.
Lower diagnosis rates in these nations are caused by a variety of causes, including a general lack of awareness and limited access to diagnostic facilities due to inadequate healthcare infrastructure. This is exacerbated by the fact that a percentage of the diagnosed population does not receive treatment for a variety of reasons. These are some of the primary factors restricting the number of patients receiving treatment, hence limiting the tibial neuromodulation devices market growth.
Principal Consultant
North America is projected to hold 34.1% of the tibial neuromodulation devices market share during the forecast period. The primary reasons for the high demand for tibial neuromodulation devices in the region include higher rates of diagnosis and treatment among the patient population, as well as increased adoption of neuromodulation devices for the treatment of chronic illnesses. This is exacerbated by the larger prevalence of chronic illnesses in the United States, as well as suitable reimbursement regulations for these devices in the country.
Europe is projected to dominate the tibial neuromodulation devices market with a share of 40.1% during the forecast period. Major factors propelling the tibial neuromodulation devices market share in Europe include a well-developed healthcare infrastructure, combined with an increase in non-invasive device approvals in the region. As a result of these factors, the sales of tibial neuromodulation devices are projected to grow rapidly from 2022 to 2032.
From 2022 to 2032, new entrants and regional players are projected to get their CE mark approvals for their non-invasive devices which is further expected to boost the tibial neuromodulation devices market growth in Europe.
How are New Entrants Revolutionizing the Tibial Neuromodulation Devices Market?
The start-up ecosystem in the tibial neuromodulation devices market is moderate with a few startups conducting clinical trials to determine the therapeutic efficacy of their products. Deep Brain Innovations LLC, Scion NeuroStim, and ALEVA NEUROTHERAPEUTICS SA are some of the startups in the tibial neuromodulation devices market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Who are some of the Key Market Players in the Tibial Neuromodulation Devices Market?
The neuromodulation devices market is consolidated, with the top four firms accounting for more than 90% of the market in 2022. Medtronic's extensive portfolio, along with strong brand awareness, widespread regional presence, and a solid distribution network, is responsible for propelling the business to market leadership in 2022.
The key market players profiled in the report include Cogentix Medical, Palex Medical SA, and Medtronic plc. Rainbow Medical Group. The key players in this market adopted product launch, partnership, and expansion as their key strategies to meet the changing consumer demands.
Recent Developments in the Tibial Neuromodulation Devices Market:
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 8.1% from 2022 to 2032 |
| Base Year for Estimation | 2022 |
| Historical Data | 2016 to 2021 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in US$ million and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled | Cogentix Medical, Palex Medical SA, Medtronic plc. Rainbow Medical Group. |
| Customization | Available Upon Request |
The tibial neuromodulation devices market is predicted to register a CAGR of 8.1 % from 2022 to 2032.
Europe region is anticipated to lead the tibial neuromodulation devices market during the forecast period.
The tibial neuromodulation devices market is likely to hold a valuation of US$ 230.7 Million by 2032.
Based on application, the overactive bladder segment dominates the tibial neuromodulation devices market.
1. Executive Summary | Tibial Neuromodulation Devices Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032
4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2021
4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Application
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Application, 2017 to 2021
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2022 to 2032
5.3.1. Faecal Incontinence
5.3.2. Overactive Bladder
5.4. Y-o-Y Growth Trend Analysis By Application, 2017 to 2021
5.5. Absolute $ Opportunity Analysis By Application, 2022 to 2032
6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By End User
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2017 to 2021
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2022 to 2032
6.3.1. Hospital
6.3.2. Ambulatory Surgical Centers
6.3.3. Clinics
6.3.4. Specialty Care Value (US$ Million)
6.4. Y-o-Y Growth Trend Analysis By End User, 2017 to 2021
6.5. Absolute $ Opportunity Analysis By End User, 2022 to 2032
7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2021
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
8.2.1. By Country
8.2.1.1. United States of America
8.2.1.2. Canada
8.2.2. By Application
8.2.3. By End User
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Application
8.3.3. By End User
8.4. Key Takeaways
9. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Application
9.2.3. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Application
9.3.3. By End User
9.4. Key Takeaways
10. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. United Kingdom
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Application
10.2.3. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Application
10.3.3. By End User
10.4. Key Takeaways
11. Asia Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. India
11.2.1.5. Malaysia
11.2.1.6. Singapore
11.2.1.7. Australia
11.2.1.8. New Zealand
11.2.1.9. Rest of United States of America
11.2.2. By Application
11.2.3. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Application
11.3.3. By End User
11.4. Key Takeaways
12. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of Middle East and Africa
12.2.2. By Application
12.2.3. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Application
12.3.3. By End User
12.4. Key Takeaways
13. Key Countries Market Analysis
13.1. United States of America
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2021
13.1.2.1. By Application
13.1.2.2. By End User
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2021
13.2.2.1. By Application
13.2.2.2. By End User
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2021
13.3.2.1. By Application
13.3.2.2. By End User
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2021
13.4.2.1. By Application
13.4.2.2. By End User
13.5. Germany
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2021
13.5.2.1. By Application
13.5.2.2. By End User
13.6. United Kingdom
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2021
13.6.2.1. By Application
13.6.2.2. By End User
13.7. France
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2021
13.7.2.1. By Application
13.7.2.2. By End User
13.8. Spain
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2021
13.8.2.1. By Application
13.8.2.2. By End User
13.9. Italy
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2021
13.9.2.1. By Application
13.9.2.2. By End User
13.10. China
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2021
13.10.2.1. By Application
13.10.2.2. By End User
13.11. Japan
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2021
13.11.2.1. By Application
13.11.2.2. By End User
13.12. South Korea
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2021
13.12.2.1. By Application
13.12.2.2. By End User
13.13. Malaysia
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2021
13.13.2.1. By Application
13.13.2.2. By End User
13.14. Singapore
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2021
13.14.2.1. By Application
13.14.2.2. By End User
13.15. Australia
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2021
13.15.2.1. By Application
13.15.2.2. By End User
13.16. New Zealand
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2021
13.16.2.1. By Application
13.16.2.2. By End User
13.17. GCC Countries
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2021
13.17.2.1. By Application
13.17.2.2. By End User
13.18. South Africa
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2021
13.18.2.1. By Application
13.18.2.2. By End User
13.19. Israel
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2021
13.19.2.1. By Application
13.19.2.2. By End User
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Application
14.3.3. By End User
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. Cogentix Medical
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. Palex Medical SA
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. Medtronic plc.
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. Rainbow Medical Group
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Boston Scientific Corporation
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. Synapse Biomedical, Inc.
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. NeuroSigma
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. Nevro Corporation
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. Neuronetics
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
16. Assumptions & Acronyms Used
17. Research Methodology
Explore Healthcare Insights
View Reports
Tibial Neuromodulation Devices Market
